Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Apr;19(4):197-208.
doi: 10.1089/omi.2015.0020.

The promise of multi-omics and clinical data integration to identify and target personalized healthcare approaches in autism spectrum disorders

Affiliations
Review

The promise of multi-omics and clinical data integration to identify and target personalized healthcare approaches in autism spectrum disorders

Roger Higdon et al. OMICS. 2015 Apr.

Abstract

Complex diseases are caused by a combination of genetic and environmental factors, creating a difficult challenge for diagnosis and defining subtypes. This review article describes how distinct disease subtypes can be identified through integration and analysis of clinical and multi-omics data. A broad shift toward molecular subtyping of disease using genetic and omics data has yielded successful results in cancer and other complex diseases. To determine molecular subtypes, patients are first classified by applying clustering methods to different types of omics data, then these results are integrated with clinical data to characterize distinct disease subtypes. An example of this molecular-data-first approach is in research on Autism Spectrum Disorder (ASD), a spectrum of social communication disorders marked by tremendous etiological and phenotypic heterogeneity. In the case of ASD, omics data such as exome sequences and gene and protein expression data are combined with clinical data such as psychometric testing and imaging to enable subtype identification. Novel ASD subtypes have been proposed, such as CHD8, using this molecular subtyping approach. Broader use of molecular subtyping in complex disease research is impeded by data heterogeneity, diversity of standards, and ineffective analysis tools. The future of molecular subtyping for ASD and other complex diseases calls for an integrated resource to identify disease mechanisms, classify new patients, and inform effective treatment options. This in turn will empower and accelerate precision medicine and personalized healthcare.

PubMed Disclaimer

Figures

<b>FIG. 1.</b>
FIG. 1.
A model schema showing data used for molecular and disease subtyping in ASD.
<b>FIG. 2.</b>
FIG. 2.
Approach to molecular and disease subtyping in ASD.
<b>FIG. 3.</b>
FIG. 3.
Comparison of expression levels across clinical features and phenotypes of mutated genes characterizing different molecular subtypes of ASD.

References

    1. Abrahams BS, Tentler D, Perederiy JV, Oldham MC, Coppola G, and Geschwind DH. (2007). Genome-wide analyses of human perisylvian cerebral cortical patterning. Proc Natl Acad Sci USA 104, 17849–17854 - PMC - PubMed
    1. Alarcon M, Abrahams BS, Stone JL, et al. (2008). Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet 82, 150–159 - PMC - PubMed
    1. American Psychiatry Association. (2013). The Diagnostic and Statistical Manual of Mental Disorders: DSM 5 bookpointUS
    1. Anagnostou E, and Taylor MJ. (2011). Review of neuroimaging in autism spectrum disorders: What have we learned and where we go from here. Mol Autism 2, 4. - PMC - PubMed
    1. Arking DE, Cutler DJ, Brune CW, et al. (2008). A common genetic variant in the neurexin superfamily member CNTNAP2 increases familial risk of autism. Am J Hum Genet 82, 160–164 - PMC - PubMed

Publication types